ACTRN12621001726842已完成未知
Palmitoylethanolamide (PEA) as an adjuvant to resistance training – can PEA augment muscle growth, power and strength in young, active, healthy adults when combined with resistance training?
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 35 Years(—)
- 性别
- All
入选标准
- •Key inclusion criteria: 1) Male or female 18-35 years of age and have had double COVID-19 vaccination done 2) recreationally active and non-resistance trained 3) have maintained a stable weight for the past 2 months (no more than ±2 kgs of weight change) 4) currently not consuming any other prescribed or non-prescribed analgesics
排除标准
- •Participants will be excluded based on the following: 1) they self-report as having had a musculoskeletal injury in the past 6 months 2) participation in structured resistance training in the past 6 months 3) allergies to any of the contents of the Levagen+ supplement 4)BMI <18.5 or BMI >28 5) currently participating in a weight loss program or special diet (e.g. Low carbohydrate, ketogenic, vegan etc) 6) current smokers 7) acute or terminal illness, functional impairment that would limit inclusion in the trial 8) use of sports supplements or pain medication in the last month 9) current chronic disease including cancer, diabetes, cardiovascular disease, chronic liver disease, and gastrointestinal disorders that affects nutrient absorption 10) cognitive impairment or inability to commit to the study and its requirements.
研究者
相似试验
尚未招募
2 期
The effect of Palmitoylethanolamide on the treatment of negative symptoms in patients with chronic schizophreniaSchizophreniaIRCT20090117001556N127Tehran University of Medical Sciences50
招募中
不适用
Palmitoylethanolamide in the treatment of major depressioMajor Depressive Disorder.Major Depressive DisorderIRCT201702181556N97Tehran University of Medical Sciences50
招募中
不适用
Palmitoylethanolamide as adjunctive treatment of Autism: A double blind and placebo controlled trialChildhood autism.Childhood autismIRCT201702171556N96Tehran University of Medical Sciences50
已完成
3 期
The effect of Palmitoylethanolamide (PEA) supplementation on the symptoms of allergic rhinitis - A double-blind placebo controlled trial.Allergic rhinitisInflammatory and Immune System - AllergiesACTRN12619001368123RDC Global Pty Ltd162
已完成
3 期
Effect of Palmitoylethanolamide (PEA) compared to a placebo on symptoms for upperrespiratory tract infection (URTI) in an Adult Population – A double blind, randomised controlledtrial.ACTRN12620000846921RDC Global Pty Ltd428
